公开(公告)号：WO03004989A3

公开(公告)日：2003-03-27

申请号：PCT/US0219669

申请日：2002-06-21

Applicant: MILLENIUM PHARMACEUTICALS INC ,  LILLIE JAMES ,  GANNAVARAPU MANJULA ,  GLATT KAREN ,  HOERSH SEBASTIAN ,  KAMATKAR SHUBHANGI ,  MERTENS MAUREEN ,  MONAHAN JOHN E ,  MYER VICKESH ,  WANG YOUZHEN ,  XU YONGYAO ,  ZHAO XUMEI ,  MEYERS RACHEL E ,  BAST ROBERT C JR ,  HORTOBAGYI GABRIEL N ,  PUSZTAI LAJOS ,  MERIC FUNDA ,  SAHIN AYSEGUL ,  MILLS GORDON B

Inventor： LILLIE JAMES ,  GANNAVARAPU MANJULA ,  GLATT KAREN ,  HOERSH SEBASTIAN ,  KAMATKAR SHUBHANGI ,  MERTENS MAUREEN ,  MONAHAN JOHN E ,  MYER VICKESH ,  WANG YOUZHEN ,  XU YONGYAO ,  ZHAO XUMEI ,  MEYERS RACHEL E ,  BAST ROBERT C JR ,  HORTOBAGYI GABRIEL N ,  PUSZTAI LAJOS ,  MERIC FUNDA ,  SAHIN AYSEGUL ,  MILLS GORDON B

IPC: C12Q1/68 ,  C12Q1/00 ,  A01N43/04 ,  A01N61/00 ,  A61K31/00 ,  A61K31/07 ,  A61K35/14 ,  A61K38/00 ,  C07H1/00 ,  C07H5/04 ,  C07H5/06 ,  C07H19/00 ,  C07H21/00 ,  C07H21/04 ,  C07K1/00 ,  C07K2/00 ,  C07K4/00 ,  C07K5/00 ,  C07K7/00 ,  C07K14/00 ,  C07K16/00 ,  C07K17/00 ,  C08B37/00 ,  G01N1/00 ,  G01N33/00 ,  G01N33/48 ,  G01N33/53 ,  G01N33/567 ,  G01N33/574

CPC classification number: C12Q1/6886 ,  C12Q2600/158

Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided.

Abstract translation: 本发明涉及新发现的与乳腺癌相关的核酸分子和蛋白质。 提供了用于检测，表征，预防和治疗人乳腺癌的组合物，试剂盒和方法。

公开(公告)号：WO2003004989A2

公开(公告)日：2003-01-16

申请号：PCT/US2002/019669

申请日：2002-06-21

Applicant: MILLENIUM PHARMACEUTICALS, INC. ,  LILLIE, James ,  GANNAVARAPU, Manjula ,  GLATT, Karen ,  HOERSH, Sebastian ,  KAMATKAR, Shubhangi ,  MERTENS, Maureen ,  MONAHAN, John, E. ,  MYER, Vickesh ,  WANG, Youzhen ,  XU, Yongyao ,  ZHAO, Xumei ,  MEYERS, Rachel, E. ,  BAST, Robert, C., Jr. ,  HORTOBAGYI, Gabriel, N. ,  PUSZTAI, Lajos ,  MERIC, Funda ,  SAHIN, Aysegul ,  MILLS, Gordon, B.

Inventor： LILLIE, James ,  GANNAVARAPU, Manjula ,  GLATT, Karen ,  HOERSH, Sebastian ,  KAMATKAR, Shubhangi ,  MERTENS, Maureen ,  MONAHAN, John, E. ,  MYER, Vickesh ,  WANG, Youzhen ,  XU, Yongyao ,  ZHAO, Xumei ,  MEYERS, Rachel, E. ,  BAST, Robert, C., Jr. ,  HORTOBAGYI, Gabriel, N. ,  PUSZTAI, Lajos ,  MERIC, Funda ,  SAHIN, Aysegul ,  MILLS, Gordon, B.

IPC: G01N

CPC classification number: C12Q1/6886 ,  C12Q2600/158

Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided.

Abstract translation: 本发明涉及新发现的与乳腺癌相关的核酸分子和蛋白质。 提供了用于检测，表征，预防和治疗人乳腺癌的组合物，试剂盒和方法。

公开(公告)号：WO2013013025A2

公开(公告)日：2013-01-24

申请号：PCT/US2012047370

申请日：2012-07-19

Applicant: MEDIMMUNE LTD ,  BEDIAN VAHE ,  WANG YOUZHEN ,  FOLTZ IAN NEVIN ,  RATHANASWAMI PALANISWAMI ,  KANG JASPAL SINGH ,  KAMAL ADEEIA ,  STEINER PHILIPP

Inventor： BEDIAN VAHE ,  WANG YOUZHEN ,  FOLTZ IAN NEVIN ,  RATHANASWAMI PALANISWAMI ,  KANG JASPAL SINGH ,  KAMAL ADEEIA ,  STEINER PHILIPP

IPC: A61K39/395

CPC classification number: C07K16/2866 ,  A61K39/3955 ,  A61K45/06 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92

Abstract: The disclosure relates to antibodies or antigen binding fragments that specifically bind to CXCR4 and inhibit the biological activity of CXCR4 and uses of such agents. More specifically the disclosure relates to fully human antibodies or antigen binding fragments directed to CXCR4 that specifically bind to CXCR4 and uses of these antibodies. Aspects of the disclosure also relate to hybridomas or other cell lines expressing such antibodies. The disclosed antibodies (including antigen binding fragments) are useful as diagnostics and for the treatment of diseases associated with the activity and/or expression of CXCR4.

Abstract translation: 本公开涉及特异性结合CXCR4并抑制CXCR4的生物学活性的抗体或抗原结合片段以及这些试剂的用途。 更具体地，本公开涉及针对CXCR4的完全人抗体或抗原结合片段，其特异性结合CXCR4和这些抗体的用途。 本公开的方面还涉及表达这种抗体的杂交瘤或其它细胞系。 所公开的抗体（包括抗原结合片段）可用作诊断和治疗与CXCR4的活性和/或表达相关的疾病。

公开(公告)号：WO2007075525A2

公开(公告)日：2007-07-05

申请号：PCT/US2006/048163

申请日：2006-12-18

Applicant: NOVARTIS AG ,  NOVARTIS PHARMA GmbH ,  JENSEN, Michael, Rugaard ,  STRAUB, Christopher, Sean ,  ZAWEL, Leigh ,  TRAN, Mary, Ann ,  WANG, Youzhen

Inventor： JENSEN, Michael, Rugaard ,  STRAUB, Christopher, Sean ,  ZAWEL, Leigh ,  TRAN, Mary, Ann ,  WANG, Youzhen

IPC: A61P35/00 ,  A61K31/16 ,  A61K31/337 ,  A61K31/425 ,  A61K31/475 ,  A61K45/06

CPC classification number: A61K31/437 ,  A61K31/16 ,  A61K31/337 ,  A61K31/425 ,  A61K31/475 ,  A61K45/06 ,  C07D471/04 ,  A61K2300/00

Abstract: The invention provides a pharmaceutical combination comprising: a) compounds that inhibit the binding of the Smac protein to IAPs; and b) a taxane, and a method for treating or preventing a proliferative disease using such a combination.

Abstract translation: 本发明提供药物组合，其包含：a）抑制Smac蛋白与IAP结合的化合物; 和b）紫杉烷类，以及使用这种组合治疗或预防增殖性疾病的方法。

公开(公告)号：WO2015145388A3

公开(公告)日：2016-01-28

申请号：PCT/IB2015052245

申请日：2015-03-26

Applicant: NOVARTIS AG ,  BAGDASARIAN LINDA ,  CONG FENG ,  JAEGER SAVINA ,  CLAUGHLIN MARGARET ELISE ,  MEYER RONALD ,  MYERS ANDREA ,  PALMER MICHAEL ROSS ,  WANG YOUZHEN ,  WOOLFENDEN STEPHEN DAVID ,  VIVANCOS ANA ,  PALMER HÉCTOR

Inventor： BAGDASARIAN LINDA ,  CONG FENG ,  JAEGER SAVINA ,  CLAUGHLIN MARGARET ELISE ,  MEYER RONALD ,  MYERS ANDREA ,  PALMER MICHAEL ROSS ,  WANG YOUZHEN ,  WOOLFENDEN STEPHEN DAVID ,  VIVANCOS ANA ,  PALMER HÉCTOR

IPC: A61K31/506 ,  A61K31/497 ,  A61K39/395 ,  A61P35/00 ,  C07K16/28

CPC classification number: A61K31/506 ,  A61K31/497 ,  A61K39/39558 ,  C07K16/2863 ,  A61K2300/00

Abstract: The present invention relates to a method of treating patients suffering from colorectal cancer, more specifically BRAF V600E -mutant or BRAF wild type, but KRAS wild type and microsatellite-unstable colorectal cancer by using a Wnt pathway inhibitor or a combination comprising a Wnt pathway inhibitor and either a BRAF inhibitor, or an EGFR inhibitor, or both. The disclosure also relates to corresponding pharmaceutical formulations, uses, methods, combinations, and related disclosure embodiments.

Abstract translation: 本发明涉及通过使用Wnt途径抑制剂或包含Wnt途径抑制剂的组合来治疗患有结肠直肠癌的患者，更具体地涉及BRAF V600E泛素或BRAF野生型但是KRAS野生型和微卫星不稳定结肠直肠癌的方法 和BRAF抑制剂或EGFR抑制剂，或两者。 本公开还涉及相应的药物制剂，用途，方法，组合和相关的公开实施方案。

公开(公告)号：WO2015145388A2

公开(公告)日：2015-10-01

申请号：PCT/IB2015/052245

申请日：2015-03-26

Applicant: NOVARTIS AG ,  BAGDASARIAN, Linda ,  CONG, Feng ,  JAEGER, Savina ,  CLAUGHLIN, Margaret Elise ,  MEYER, Ronald ,  MYERS, Andrea ,  PALMER, Michael Ross ,  WANG, Youzhen ,  WOOLFENDEN, Stephen David ,  VIVANCOS, Ana ,  PALMER, Héctor

Inventor： BAGDASARIAN, Linda ,  CONG, Feng ,  JAEGER, Savina ,  CLAUGHLIN, Margaret Elise ,  MEYER, Ronald ,  MYERS, Andrea ,  PALMER, Michael Ross ,  WANG, Youzhen ,  WOOLFENDEN, Stephen David ,  VIVANCOS, Ana ,  PALMER, Héctor

IPC: A61K31/506

CPC classification number: A61K31/506 ,  A61K31/497 ,  A61K39/39558 ,  C07K16/2863 ,  A61K2300/00

Abstract: The present invention relates to a method of treating patients suffering from colorectal cancer, more specifically BRAF V600E -mutant or BRAF wild type, but KRAS wild type and microsatellite-unstable colorectal cancer by using a Wnt pathway inhibitor or a combination comprising a Wnt pathway inhibitor and either a BRAF inhibitor, or an EGFR inhibitor, or both. The disclosure also relates to corresponding pharmaceutical formulations, uses, methods, combinations, and related disclosure embodiments.

Abstract translation: 本发明涉及通过使用Wnt途径抑制剂或包含Wnt途径抑制剂的组合来治疗患有结肠直肠癌的患者，更具体地涉及BRAF V600E泛素或BRAF野生型但是KRAS野生型和微卫星不稳定结肠直肠癌的方法 和BRAF抑制剂或EGFR抑制剂，或两者。 本公开还涉及相应的药物制剂，用途，方法，组合和相关的公开实施方案。

公开(公告)号：WO02085298A3

公开(公告)日：2003-05-22

申请号：PCT/US0212612

申请日：2002-04-19

Applicant: MILLENNIUM PHARM INC ,  LILLIE JAMES ,  PALERMO ADAM ,  WANG YOUZHEN ,  STEINMANN KATHLEEN ,  ELIAS JOSH ,  MERTENS MAUREEN

Inventor： LILLIE JAMES ,  PALERMO ADAM ,  WANG YOUZHEN ,  STEINMANN KATHLEEN ,  ELIAS JOSH ,  MERTENS MAUREEN

IPC: C07K14/47 ,  C12N15/12 ,  C12Q1/68 ,  G01N33/574 ,  G01N33/53

CPC classification number: G01N33/57415 ,  C07K14/47 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N2500/00 ,  G01N2800/52

Abstract: The invetion relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human breat cancers. A variety of market genes are provided, wherein changes in the levels of expression of one or more of the marker genes is correlated with the presence of breat cancer.

Abstract translation: 这种侵袭涉及用于检测，表征，预防和治疗人类呼吸癌的组合物，试剂盒和方法。 提供了各种市场基因，其中一个或多个标记基因的表达水平的变化与呼吸癌的存在相关。

公开(公告)号：WO2016054483A1

公开(公告)日：2016-04-07

申请号：PCT/US2015/053677

申请日：2015-10-02

Applicant: NOVARTIS AG ,  FAIRHURST, Robin, Alec ,  FURET, Pascal ,  KNÖPFEL, Thomas ,  LEBLANC, Catherine ,  LIAO, Lv ,  MAH, Robert ,  NIMSGERN, Pierre ,  RIPOCHE, Sebastien ,  XIONG, Jing ,  ZHAO, Xianglin ,  HAN, Bo ,  WANG, Can ,  PORTER, Dale ,  BUSCHMANN, Nicole ,  GRAUS PORTA, Diana ,  HAEFLIGER, Carolina ,  MURAKAMI, Masato ,  PALMER, Michael ,  WANG, Youzhen ,  WEISS, Andreas

Inventor： FAIRHURST, Robin, Alec ,  FURET, Pascal ,  KNÖPFEL, Thomas ,  LEBLANC, Catherine ,  LIAO, Lv ,  MAH, Robert ,  NIMSGERN, Pierre ,  RIPOCHE, Sebastien ,  XIONG, Jing ,  ZHAO, Xianglin ,  HAN, Bo ,  WANG, Can ,  PORTER, Dale ,  BUSCHMANN, Nicole ,  GRAUS PORTA, Diana ,  HAEFLIGER, Carolina ,  MURAKAMI, Masato ,  PALMER, Michael ,  WANG, Youzhen ,  WEISS, Andreas

IPC: A61K31/4375 ,  A61K31/437 ,  A61K31/4353 ,  A61K31/506 ,  A61K31/5383 ,  A61K31/5377 ,  A61K31/501 ,  A61P35/00

CPC classification number: A61K31/4375 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/55 ,  A61P35/00

Abstract: The present invention relates to therapeutic uses of compounds of formula (I) or a pharmaceutically acceptable salt thereof.

Abstract translation: 本发明涉及式（I）化合物或其药学上可接受的盐的治疗用途。

公开(公告)号：WO2013013025A3

公开(公告)日：2013-01-24

申请号：PCT/US2012/047370

申请日：2012-07-19

Applicant: MEDIMMUNE LIMITED ,  BEDIAN, Vahe ,  WANG, Youzhen ,  FOLTZ, Ian, Nevin ,  RATHANASWAMI, Palaniswami ,  KANG, Jaspal, Singh ,  KAMAL, Adeeia ,  STEINER, Philipp

Inventor： BEDIAN, Vahe ,  WANG, Youzhen ,  FOLTZ, Ian, Nevin ,  RATHANASWAMI, Palaniswami ,  KANG, Jaspal, Singh ,  KAMAL, Adeeia ,  STEINER, Philipp

IPC: A61K39/395

Abstract: The disclosure relates to antibodies or antigen binding fragments that specifically bind to CXCR4 and inhibit the biological activity of CXCR4 and uses of such agents. More specifically the disclosure relates to fully human antibodies or antigen binding fragments directed to CXCR4 that specifically bind to CXCR4 and uses of these antibodies. Aspects of the disclosure also relate to hybridomas or other cell lines expressing such antibodies. The disclosed antibodies (including antigen binding fragments) are useful as diagnostics and for the treatment of diseases associated with the activity and/or expression of CXCR4.

公开(公告)号：WO2007075525A3

公开(公告)日：2007-11-15

申请号：PCT/US2006048163

申请日：2006-12-18

Applicant: NOVARTIS AG ,  NOVARTIS PHARMA GMBH ,  JENSEN MICHAEL RUGAARD ,  STRAUB CHRISTOPHER SEAN ,  ZAWEL LEIGH ,  TRAN MARY ANN ,  WANG YOUZHEN

Inventor： JENSEN MICHAEL RUGAARD ,  STRAUB CHRISTOPHER SEAN ,  ZAWEL LEIGH ,  TRAN MARY ANN ,  WANG YOUZHEN

IPC: A61P35/00 ,  A61K31/16 ,  A61K31/337 ,  A61K31/425 ,  A61K31/475 ,  A61K45/06

CPC classification number: A61K31/437 ,  A61K31/16 ,  A61K31/337 ,  A61K31/425 ,  A61K31/475 ,  A61K45/06 ,  C07D471/04 ,  A61K2300/00

Abstract: The invention provides a pharmaceutical combination comprising: a) compounds that inhibit the binding of the Smac protein to IAPs; and b) a taxane, and a method for treating or preventing a proliferative disease using such a combination.

Abstract translation: 本发明提供药物组合，其包含：a）抑制Smac蛋白与IAP结合的化合物; 和b）紫杉烷，以及使用这种组合治疗或预防增殖性疾病的方法。